Unintentional weakness of cancers: The MEK-ERK pathway as a double-edged sword

Molecular Cancer Research

Volumn 11, Issue 10, 2013, Pages 1125-1128

  Suda, Kenichi ^a,b   Mitsudomi, Tetsuya ^a  

^a KINKI UNIVERSITY   (Japan)

^b KYUSHU UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

B RAF KINASE; BOSUTINIB; CRIZOTINIB; DABRAFENIB; DASATINIB; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; GEFITINIB; IMATINIB; MITOGEN ACTIVATED PROTEIN KINASE; NILOTINIB; PONATINIB; VEMURAFENIB; ANTINEOPLASTIC AGENT; EPIDERMAL GROWTH FACTOR RECEPTOR; INDOLE DERIVATIVE; SULFONAMIDE;

CANCER CELL; CANCER RESISTANCE; CELL PROLIFERATION; CELL STRUCTURE; CHRONIC MYELOID LEUKEMIA; DRUG DEPENDENCE; DRUG DOSE REGIMEN; ENZYME ACTIVATION; GASTROINTESTINAL STROMAL TUMOR; GENE MUTATION; GENE OVEREXPRESSION; HUMAN; LUNG ADENOCARCINOMA; LUNG CANCER; MELANOMA; ONCOGENE; PRIORITY JOURNAL; REVIEW; SIGNAL TRANSDUCTION; UNSPECIFIED SIDE EFFECT; ANIMAL; ANTAGONISTS AND INHIBITORS; CARCINOMA, LEWIS LUNG; DRUG RESISTANCE; GENETICS; MELANOMA, EXPERIMENTAL; METABOLISM; MOLECULARLY TARGETED THERAPY; NEOPLASMS; TUMOR MICROENVIRONMENT;

ANIMALS; ANTINEOPLASTIC AGENTS; CARCINOMA, LEWIS LUNG; DRUG RESISTANCE, NEOPLASM; HUMANS; INDOLES; MAP KINASE SIGNALING SYSTEM; MELANOMA, EXPERIMENTAL; MOLECULAR TARGETED THERAPY; NEOPLASMS; PROTO-ONCOGENE PROTEINS B-RAF; RECEPTOR, EPIDERMAL GROWTH FACTOR; SULFONAMIDES; TUMOR MICROENVIRONMENT;

EID: 84886440357     PISSN: 15417786     EISSN: 15573125     Source Type: Journal    
DOI: 10.1158/1541-7786.MCR-13-0228     Document Type: Review

References (25)

1. Druker BJ, Talpaz M, Resta DJ, Peng B, Buchdunger E, Ford JM, et al. Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N Engl J Med 2001;344:1031-7.
2. Jain P, Kantarjian H, Cortes J. Chronic myeloid leukemia: overview of new agents and comparative analysis. Curr Treat Options Oncol 2013;14:127-43.
3. Mitsudomi T, Morita S, Yatabe Y, Negoro S, Okamoto I, Tsurutani J, et al. Gefitinib versus cisplatin plus docetaxel in patients with nonsmall- cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial. Lancet Oncol 2010;11:121-8.
4. Maemondo M, Inoue A, Kobayashi K, Sugawara S, Oizumi S, Isobe H, et al. Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR. N Engl J Med 2010;362:2380-8.
5. Rosell R, Carcereny E, Gervais R, Vergnenegre A, Massuti B, Felip E, et al. Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-smallcell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial. Lancet Oncol 2012;13:239-46.
6. Yang JC-H, Schuler MH, Yamamoto N, O,Byrne KJ, Hirsch V, Mok T, et al. LUX-Lung 3: A randomized, open-label, phase III study of afatinib versus pemetrexed and cisplatin as first-line treatment for patients with advanced adenocarcinoma of the lung harboring EGFR-activating mutations. J Clin Oncol 30, 2012 (suppl; abstr LBA7500).
7. Kwak EL, Bang YJ, Camidge DR, Shaw AT, Solomon B, Maki RG, et al. Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer. N Engl J Med 2011;363:1693-703.
8. Chapman PB, Hauschild A, Robert C, Haanen JB, Ascierto P, Larkin J, et al. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med 2011;364:2507-16.
9. Hauschild A, Grob JJ, Demidov LV, Jouary T, Gutzmer R, Millward M, et al. Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial. Lancet 2012;380:358-65.
10. Sequist LV, Waltman BA, Dias-Santagata D, Digumarthy S, Turke AB, Fidias P, et al. Genotypic and histological evolution of lung cancers acquiring resistance to EGFR inhibitors. Sci Transl Med 2011;3: 75ra26.
11. Suda K, Mizuuchi H, Maehara Y, Mitsudomi T. Acquired resistance mechanisms to tyrosine kinase inhibitors in lung cancer with activating epidermal growth factor receptor mutation-diversity, ductility, and destiny. Cancer Metast Rev 2012;31:807-14.
12. Branford S, Rudzki Z, Walsh S, Grigg A, Arthur C, Taylor K, et al. High frequency of point mutations clustered within the adenosine triphosphate-binding region of BCR/ABL in patients with chronic myeloid leukemia or Ph-positive acute lymphoblastic leukemia who develop imatinib (STI571) resistance. Blood 2002;99:3472-5.
13. Tamborini E, Bonadiman L, Greco A, Albertini V, Negri T, Gronchi A, et al. A new mutation in the KIT ATP pocket causes acquired resistance to imatinib in a gastrointestinal stromal tumor patient. Gastroenterology 2004;127:294-9.
14. Kobayashi S, Boggon TJ, Dayaram T, Janne PA, Kocher O, Meyerson M, et al. EGFRmutation and resistance of non-small-cell lung cancer to gefitinib. N Engl J Med 2005;352:786-92.
15. Weisberg E, Griffin JD. Mechanism of resistance to the ABL tyrosine kinase inhibitor STI571 in BCR/ABL-transformed hematopoietic cell lines. Blood 2000;95:3498-505.
16. Suda K, Tomizawa K, Osada H, Maehara Y, Yatabe Y, Sekido Y, et al. Conversion from the "oncogene addiction" to "drug addiction" by intensive inhibition of the EGFR and MET in lung cancer with activating EGFR mutation. Lung Cancer 2012;76:292-9.
17. Shi H, Moriceau G, Kong X, Lee MK, Lee H, Koya RC, et al. Melanoma whole-exome sequencing identifies (V600E)B-RAF amplificationmediated acquired B-RAF inhibitor resistance. Nat Commun 2012;3: 724.
18. Das Thakur M, Salangsang F, Landman AS, Sellers WR, Pryer NK, Levesque MP, et al. Modelling vemurafenib resistance in melanoma reveals a strategy to forestall drug resistance. Nature 2013;494: 251-5.
19. Serrano M, Lin AW, McCurrach ME, Beach D, Lowe SW. Oncogenic ras provokes premature cell senescence associated with accumulation of p53 and p16INK4a. Cell 1997;88:593-602.
20. Zhu J, Woods D, McMahon M, Bishop JM. Senescence of human fibroblasts induced by oncogenic Raf. Genes Dev 1998;12:2997-3007.
21. Woods D, Parry D, Cherwinski H, Bosch E, Lees E, McMahon M. Rafinduced proliferation or cell cycle arrest is determined by the level of Raf activitywith arrestmediatedbyp21Cip1. MolCellBiol1997;17:5598-611.
22. Sturm OE, Orton R, Grindlay J, Birtwistle M, Vyshemirsky V, Gilbert D, et al. The mammalian MAPK/ERK pathway exhibits properties of a negative feedback amplifier. Sci Signal 2010;3:ra90.
23. Research Watch. Discontinuous vemurafenib dosing delays resistance. Cancer Discov 2013;3:247.
24. Riely GJ, Kris MG, Zhao B, Akhurst T, Milton DT, Moore E, et al. Prospective assessment of discontinuation and reinitiation of erlotinib or gefitinib in patients with acquired resistance to erlotinib or gefitinib followed by the addition of everolimus. Clin Cancer Res 2007;13: 5150-5.
25. Chmielecki J, Foo J, Oxnard GR, Hutchinson K, Ohashi K, Somwar R, et al. Optimization of dosing for EGFR-mutant non-small cell lung cancer with evolutionary cancer modeling. Sci Transl Med 2011;3: 90ra59.